Press & News

The next generation biopharmaceuticals

Press releases

2020-05-15

Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035 – A Phase 2 Drug Candidate with Best-in-Class Potential for Auto-Immune Diseases

Solna, Sweden & Shanghai, China, May 15, 2020. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases.[read more]

Older press releases

2020-04-30

Affibody Announces Option Exercise by Daewoong

Solna, Sweden, April 30, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced that its partner Daewoong, a South Korea-based pharmaceutical company, has exercised an option under the companies’ ongoing...[read more]

2020-02-21

Year End Report 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Full Year Report for 2019.[read more]

2020-02-03

Notice of EGM (Kallelse till extra bolagsstämma)

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 17 februari 2020 kl 14.00 i bolagets lokaler, Scheeles väg 2, Solna.[read more]

Affibodys latest Press releases

2020-06-15

Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis

Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced positive top-line data from...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information